- Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors
-
Pin1 (Protein interacting with NIMA1) is a cis–trans isomerase and promotes the amide bond rotation of phosphoSer/Thr-Pro motifs in its substrates. Inhibition of Pin1 might be a novel strategy for developing anticancer agents. Herein, a series of pyrimidi
- Cui, Guonan,Jin, Jing,Chen, Hualong,Cao, Ran,Chen, Xiaoguang,Xu, Bailing
-
-
Read Online
- ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
-
Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).
- -
-
Paragraph 0089; 0090
(2013/04/23)
-
- PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES
-
Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
- -
-
Page/Page column 80-81
(2012/12/13)
-
- Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations
-
This paper describe the structural optimization of a hit compound, N 2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine- 2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N 8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.
- Yang, Jiao,Wang, Li-Jiao,Liu, Jing-Jing,Zhong, Lei,Zheng, Ren-Lin,Xu, Yong,Ji, Pan,Zhang, Chun-Hui,Wang, Wen-Jing,Lin, Xing-Dong,Li, Lin-Li,Wei, Yu-Quan,Yang, Sheng-Yong
-
p. 10685 - 10699
(2013/02/22)
-
- Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury
-
In this Letter we describe the optimization of an aminopurine lead (1) with modest potency and poor overall kinase selectivity which led to the identification of a series of potent, selective JNK inhibitors. Improvement in kinase selectivity was enabled by introduction of an aliphatic side chain at the C-2 position. CC-359 (2) was selected as a potential clinical candidate for diseases manifested by ischemia reperfusion injury.
- Krenitsky, Véronique Plantevin,Delgado, Mercedes,Nadolny, Lisa,Sahasrabudhe, Kiran,Ayala, Leticia,Clareen, Steven S.,Hilgraf, Robert,Albers, Ronald,Kois, Adam,Hughes, Kevin,Wright, Jonathan,Nowakowski, Jacek,Sudbeck, Elise,Ghosh, Sutapa,Bahmanyar, Sogole,Chamberlain, Philip,Muir, Jeff,Cathers, Brian E.,Giegel, David,Xu, Li,Celeridad, Maria,Moghaddam, Mehran,Khatsenko, Oleg,Omholt, Paul,Katz, Jason,Pai, Sema,Fan, Rachel,Tang, Yang,Shirley, Michael A.,Benish, Brent,Blease, Kate,Raymon, Heather,Bhagwat, Shripad,Henderson, Ian,Cole, Andrew G.,Bennett, Brydon,Satoh, Yoshitaka
-
scheme or table
p. 1427 - 1432
(2012/04/04)
-
- Heteroaryl imidazolone derivatives as jak inhibitors
-
New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
- -
-
Page/Page column 35-36
(2012/01/06)
-
- HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS
-
New heteroaryl imidazolone derivatives having the chemical structure of formula (I) disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
- -
-
Page/Page column 83
(2012/01/06)
-
- 5-MEMBERED ANNELATED HETEROCYCLIC PYRIMIDINES AS KINASE INHIBITORS
-
This invention comprises the novel compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, Q1, Q2, X1, X2, Y and Z have defined meanings, having
- -
-
Page/Page column 41
(2008/06/13)
-
- TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
-
This invention concerns compounds of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochernically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 represents hydrogen; aryl; formyl; C1-6 alkylcarbonyl; C1-6 a]kyl; C1-6 alkyloxycarbonyl; C1-6 alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonytoxy; or optionally substituted C1-6 alkyloxyCl-6alkylcarbonyl; X1 represents a direct bond; -(CH2)n3- or -(CH2)n4-X1a-X1b-; R2 represents optionally substituted C3-7CYCloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatorn selected from 0, S or N; benzoxazolyl or a radical of formula (a-1); X2 represents a direct bond; -NR1-NR1-(CH2)N3 -; -0-; -0-(CH2)n3-; -C(=O)-; -C(=O)- (CH2)n3-; -C(=O)-NR5-(CH2)n3-; -C(=S)-; -S-; -S(=O)n1-; -(CH2)n3-; -(CH2)n4-X1a-X1b-; -X1a.-X1b-(CH2)n4-; -S(=O)n1-NR5-(CH2)n3-NR5_ or -S(=O)n1,-NR5 -(CH2)n3-; R3 represents an optionally substituted 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from 0, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from 0, S or N; R4 represents hydrogen; halo; hydroxy; optionally substituted C1-4alkyl; optionally substituted C2-4alkenyl or C2-4alkynyl; polyhaloC1-3alkyl; optionally substituted C1-4alkyloxy; polyhaloC1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio; C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhaloC1-4alkylcarbonyl; nitro; cyano; carboxyl; NR9R10; C(=O)NR9R10;-NR5_C(=O)-NR9R10; -NR5-C(=O)-R5; -S(=O) n1,-R11 -NR5-S(=O)n1,-R11 -S-CN; -NR5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.
- -
-
Page/Page column 54
(2010/02/10)
-